Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 12/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 5/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5844308 | 0.89 | CYSLTR1 (0.48) | CYSLTR1GRM2CYSLTR2PDE4APDE4B | |
| SCHEMBL4035673 | 0.84 | CYP2C9 (0.58) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6603007 | 0.75 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5778745 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5775461 | 0.73 | SLC40A1 (0.48) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5776441 | 0.71 | CYP2C9 (0.47) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5777013 | 0.71 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL2893372 | 0.71 | CYSLTR1 (0.60) | CYSLTR1GRM2CYSLTR2CYP2C9 | |
| SCHEMBL4937170 | 0.70 | CYSLTR1 (0.52) | CYSLTR1GRM2CYSLTR2CYP2C9 | |
| SCHEMBL5779532 | 0.70 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | CYSLTR1 3931/4885GRM2 3952/4885CYSLTR2 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.